Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
Two depot neuroleptics (flupenthixol plamitate and clopenthixol decanoate) used for at least 15 months were withdrawn in 32 schizophrenic outpatients belonging to the most symptom-free and social cohort of a total patient population. They all had only slight schizophrenic symptoms, were well adapted in the community, and had been free from relapse for at least 2 years before the study. They were assessed by means of rating scales every month during the first six months and then after 9 and 12 months. After the one-year trial 26 patients had relapsed. Moreover, after the control period further 4 out of 6 patients relapsed during the following drug-free year. These results indicate the necessity of a long follow-up period after withdrawal of depot neuroleptics. Moreover, the results suggest that periodical drug-free periods of about 3 months are appropriate in symptom-poor patients during long-term treatment with long-acting antipsychotic drugs.
D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D003006:Clopenthixol / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005475:Flupenthixol / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012559:Schizophrenia / Q000188:drug therapy*; D012917:Social Adjustment; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D003006:Clopenthixol; D005475:Flupenthixol